Head-To-Head Review: Rein Therapeutics (NASDAQ:RNTX) vs. Vitro Diagnostics (OTCMKTS:VODG)

Vitro Diagnostics (OTCMKTS:VODG) and Rein Therapeutics (NASDAQ:RNTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Vitro Diagnostics and Rein Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vitro Diagnostics	-381.47%	N/A	-152.79%
Rein Therapeutics	N/A	-510.35%	-40.77%

Earnings and Valuation

This table compares Vitro Diagnostics and Rein Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vitro Diagnostics	$1.86 million	N/A	-$9.87 million	($2.21)	-0.18
Rein Therapeutics	N/A	N/A	-$62.88 million	($2.63)	-0.47

Vitro Diagnostics has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than Vitro Diagnostics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

90.9% of Rein Therapeutics shares are held by institutional investors. 27.7% of Vitro Diagnostics shares are held by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Vitro Diagnostics and Rein Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vitro Diagnostics	0	0	0	0	0.00
Rein Therapeutics	1	0	2	0	2.33

Rein Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 545.16%. Given Rein Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than Vitro Diagnostics.

About Vitro Diagnostics

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.

About Rein Therapeutics

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.